Bioinformatics Partnering Terms and Agreements

  • October 2014
  • -
  • Currentpartnering
  • -
  • 1268 pages

Summary
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in bioinformatics partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for bioinformatics

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.

Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2009, including financial terms where available, including over 1500 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading bioinformatics deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a listing of the top big biotech companies with a brief summary followed by a listing of bioinformatics deals where available, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2009. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of bioinformatics deal trends since 2009
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of bioinformatics agreements with numerous real life case studies
•Comprehensive access to over 1500 bioinformatics deals entered into by the world’s biopharma companies
• Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a bioinformatics agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Benefits
Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of bioinformatics deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of bioinformatics agreements with numerous real life case studies
Comprehensive access to over 1500 bioinformatics deal documents entered into by the world’s biopharma companies
Detailed access to actual bioinformatics contracts
Provides insight into deals dentered by top 50 big pharma and top big biotech companies
Insight into the terms included in a bioinformatics agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bioinformatics dealmaking

2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Big pharma bioinformatics dealmaking activity
2.4. Big Biotech bioinformatics dealmaking activity
2.5. Most active bioinformatics dealmakers
2.6. Bioinformatics partnering by deal type
2.7. Bioinformatics partnering by disease type
2.9. Average deal terms for bioinformatics partnering
2.9.1 Bioinformatics partnering headline values
2.9.2 Bioinformatics deal upfront payments
2.9.3 Bioinformatics deal milestone payments
2.9.4 Bioinformatics royalty rates

Chapter 3 - Leading bioinformatics deals

3.1. Introduction
3.2. Top bioinformatics deals by value

Chapter 4 - Big pharma bioinformatics deals

4.1. Introduction
4.2. How to use big pharma bioinformatics partnering deals
4.3. Big pharma bioinformatics partnering company profiles
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Chugai Pharmaceutical
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
GlaxoSmithKline
Grifols
Hospira
Johnson and Johnson
Lundbeck
Menarini
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shire
Takeda
Teva
UCB
Valeant

Chapter 5 - Big biotech bioinformatics deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech bioinformatics partnering company profiles
Actelion
Dendreon
Vertex Pharmaceuticals

Chapter 6 - Bioinformatics contracts dealmaking directory

6.1. Introduction
6.2. Bioinformatics contracts dealmaking directory- By company A-Z
6.3. Bioinformatics contracts dealmaking directory- By deal type
Asset purchase
Co-development
Collaborative RandD
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Licensing
Litigation
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Technology transfer
6.4. Bioinformatics contracts dealmaking directory- By therapy area
Cardiovascular
Gastrointestinal
Infectives
Metabolic
Oncology

Chapter 7 - Bioinformatics dealmaking by technology type
Bioinformatics
Software tools
Chapter 8 - Partnering resource center
8.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Upgrades to subscription access products
Order Form - Reports

Appendix

Appendix 1 - Bioinformatics deals by company A-Z
Appendix 2 - Bioinformatics deals by stage of development
Appendix 3 - Bioinformatics deals by deal type
Appendix 4 - Bioinformatics deals by therapy area

Table of figures

Figure 1: Bioinformatics partnering since 2009
Figure 2: Big pharma - top 50 - bioinformatics deals 2009 to 2014
Figure 3: Big pharma biomarker deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - bioinformatics deals 2009 to 2014
Figure 5: Big biotech biomarker deal frequency - 2009 to 2014
Figure 6: Active bioinformatics dealmaking activity- 2009 to 2014
Figure 7: Bioinformatics partnering by deal type since 2009
Figure 8: Bioinformatics partnering by disease type since 2009
Figure 10: Bioinformatics deals with a headline value by year - 2014
Figure 11: Bioinformatics deals with a headline value by year- 2013
Figure 12: Bioinformatics deals with a headline value by year- 2012
Figure 13: Bioinformatics deals with a headline value by year- 2011
Figure 14: Bioinformatics deals with a headline value by year- 2010
Figure 15: Bioinformatics deals with a headline value by year- 2009
Figure 16: Summary median headline value by year, 2009-2014
Figure 17: Bioinformatics deals with an upfront value by year, 2014
Figure 18: Bioinformatics deals with an upfront value by year- 2013
Figure 19: Bioinformatics deals with an upfront value by year- 2012
Figure 20: Bioinformatics deals with an upfront value by year- 2011
Figure 21: Bioinformatics deals with an upfront value by year- 2010
Figure 22: Bioinformatics deals with an upfront value by year- 2009
Figure 16: Summary median headline value by year, 2009-2014
Figure 25: Bioinformatics deals with a milestone value by year, 2014
Figure 26: Bioinformatics deals with a milestone value by year- 2013
Figure 27: Bioinformatics deals with a milestone value by year- 2012
Figure 28: Bioinformatics deals with a milestone value by year- 2011
Figure 29: Bioinformatics deals with a milestone value by year- 2010
Figure 30: Bioinformatics deals with a milestone value by year- 2009
Figure 32: Bioinformatics deals with a royalty rate value by year, 2014
Figure 33: Bioinformatics deals with a royalty rate value by year- 2013
Figure 34: Bioinformatics deals with a royalty rate value by year- 2012
Figure 35: Bioinformatics deals with a royalty rate value by year- 2011
Figure 36: Bioinformatics deals with a royalty rate value by year- 2010
Figure 37: Bioinformatics deals with a royalty rate value by year- 2009
Figure 35: Summary median a royalty rate by year, 2009-2014
Figure 45: Top bioinformatics deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Trends

Global Next-generation Sequencing Trends

  • $ 12 500
  • Industry report
  • September 2014
  • by Frost & Sullivan

An End-user Perspective The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house ...

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report discusses market growth, size and opportunities with respect to applications, geographic region and technologies. Forecast trends and revenue are given through 2019. Major players, ...

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report provides an overview of the current state of the microRNA (miRNA) market, focusing mainly on continuing research endeavors, newly emerging sophisticated tools, reagents, techniques, ...

Global Bioinformatics Industry

July 2014 $ 4 950

3 Companies

Company Profiles

ForeverGreen IP L.L.C.

United States

Seattle Genetics Inc.

United States

Genentech Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.